

Supporting Information

**Antibody-Modified Hydroxyapatite Surfaces for the
Efficient Capture of Bladder Cancer Cells within
Patient's Urine without Recourse to Any Sample Pre-
treatment**

Wei Zhang ^{a,b} Kai Zhao ^c Craig E. Banks ^{*,d} and Ying Zhang ^{*,a}

^aCollege of Science, Huazhong Agricultural University, Wuhan 430072, P.R. China.
E-mail: zhangying84@mail.hzau.edu.cn

^b Wuhan Institute of Marine Electric Propulsion, Wuhan 430064, P.R. China.

^c Huazhong University of Science and Technology Tongji Medical College, Wuhan 430030, P.R. China.

^d Faculty of Science and Engineering, Manchester Metropolitan University, Chester Street, Manchester M1 5GD, UK.




Figure S1. The outer (a) and inner surface (b) of conch shell as defined within this work.




Figure S2. Fluorescence characterization and cell number statistical results of control groups for cell-capture experiments. Herein, the normal human urine samples collected from 25 normal people were utilized for parallel experiment, aimed to find out the interferences in urine environment. The whole process was kept pace with that for the patient urine. ($p<0.05$)

Table S1. Corresponding disease information to the urine samples used within this work.

| Sample No. ^{a)} | Gender of patient | Age of patient | Region of patient | Urine appearance | Disease | Grade/ stage |
|--------------------------|-------------------|----------------|-------------------|------------------|------------------------------|-------------------------|
| BC-1 | Male | 50 | Hubei | Clear | Bladder cancer | G3/ T2 |
| BC-2 | Male | 87 | Hubei | Blood | Bladder cancer | G3/ T3 |
| BC-3 | Female | 64 | Hubei | Clear | Bladder cancer | G3/T2 |
| BP-1 | Male | 72 | Hubei | Blood | Bladder polyp | / |
| BC-4 | Female | 57 | Hubei | Cloudy | Bladder cancer | G1/T1 |
| BC-5 | Female | 67 | Hubei | Clear | Bladder cancer | G3/ T2 |
| BPH-1 | Male | 77 | Hubei | Cloudy | Benign prostatic hyperplasia | / |
| BC-6 | Male | 81 | Jiangxi | Clear | Bladder cancer | G3/T2 |
| BC-7 | Female | 72 | Jiangxi | Clear | Bladder cancer | G1/T1 |
| BC-8 | Male | 28 | Jiangxi | Blood | Bladder cancer | G1/T1 |
| BC-9 | Male | 62 | Jiangxi | Clear | Bladder cancer | G1/T1 |
| BC-10 | Male | 63 | Jiangxi | Cloudy | Bladder cancer | G3/T1 |
| BC-11 | Female | 47 | Jiangxi | Cloudy | Bladder cancer | G3/T2 |
| BC-12 | Male | 72 | Jiangxi | Cloudy | Bladder cancer | G3/T3 |
| BC-13 | Male | 63 | Jiangxi | Clear | Bladder cancer | G3/T1 |
| BC-14 | Female | \ | Henan | Blood | Bladder cancer | High-level non invasion |
| BC-15 | Female | 43 | Henan | Clear | Bladder cancer | |
| BC-16 | Male | 41 | Henan | Clear | Bladder cancer | |
| BC-17 | Female | 45 | Henan | Blood | Bladder cancer | |
| BC-18 | Male | 66 | Henan | Cloudy | Bladder cancer | |
| BC-19 | Male | 56 | Henan | Blood | Bladder cancer | G3/T3 |
| BC-20 | Male | 66 | Henan | Cloudy | Bladder cancer | Low potential |

a) Fresh morning urine




Figure S3. Classification of patients' urine samples




Figure S4. Three typical appearances of urine samples used in this research and corresponding typical fluorescence micrographs: (a) clear (normal), (b) cloudy and (c) blood (*gross hematuria*).